Cadenza Bio

Published in Scientific Reports, a Nature Portfolio journal, the study details dual acting small molecules that restore myelin, modulate inflammation, and improve visual pathway function in preclinical MS models. OKLAHOMA CITY, Oct. 9, 2025 /PRNewswire/ -- Cadenza Bio, Inc. today announced that a collaborative study, "Chloroindazole based Estrogen Receptor β ligands with favorable pharmacokinetics promote functional remyelination and visual recovery," has been published in Scientific Reports ( h

May 31, 2024 – Cadenza Bio announced that it will be attending the BIO International Convention June 3-6, 2024 in San Diego, California. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech. The event is expected to bring together over 18,500 industry leaders from across the globe.

OKLAHOMA CITY, January 9, 2025 /PRNewswire/ -- Cadenza Bio, Inc., a preclinical biotechnology company dedicated to developing small-molecule therapies for demyelinating and inflammatory disease, proudly announces the formation of its Women’s Health Scientific Advisory Board (SAB). This expert panel will provide strategic guidance for advancing research and development in support of Cadenza Bio’s Endometriosis program. Comprising key leaders across academic and clinical research, the Women’s Heal

February 7, 2025 – Cadenza Bio, Inc., a leading preclinical biotechnology company dedicated to developing novel small-molecule drugs for demyelinating and inflammatory diseases, today announced a research collaboration agreement with Tufts University to advance its innovative endometriosis program. Endometriosis is a debilitating gynecological disease affecting approximately 1 in 10 women globally. Despite its prevalence, treatment options remain limited, and there exists an unmet need for thera

Multiple Sclerosis Scientific Advisory Board

Cadenza Bio is a preclinical biotechnology company focused on developing a series of novel small-molecule drugs for the treatment of demyelinating and inflammatory diseases.